Halozyme Therapeutics, Inc. (BMV:HALO)
Mexico · Delayed Price · Currency is MXN 1,121.86
+103.35 (10.15%)
At close: Jul 29, 2025
Halozyme Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
Net Income | 557.28 | 444.09 | 281.59 | 202.13 | 402.71 | 129.09 | Upgrade |
Depreciation & Amortization | 81.73 | 81.31 | 84.86 | 49.64 | 3 | 3.28 | Upgrade |
Stock-Based Compensation | 46.87 | 43.39 | 36.62 | 24.4 | 20.82 | 17.2 | Upgrade |
Other Adjustments | -17.57 | -1.51 | 22.9 | 53.29 | -151.03 | 14.77 | Upgrade |
Change in Receivables | -101.82 | -74.25 | -3.34 | -83.94 | 6.76 | -38.29 | Upgrade |
Changes in Inventories | -20.87 | -67.38 | -26.88 | -17.48 | 7.37 | -31.39 | Upgrade |
Changes in Accounts Payable | 6.53 | 46.99 | -12.55 | 24.54 | 1.17 | -41.21 | Upgrade |
Changes in Unearned Revenue | - | - | - | -2.49 | -0.75 | 0.51 | Upgrade |
Changes in Other Operating Activities | 4.11 | 6.42 | 5.37 | -9.97 | 9.41 | 1.49 | Upgrade |
Operating Cash Flow | 547.78 | 479.06 | 388.57 | 240.11 | 299.44 | 55.45 | Upgrade |
Operating Cash Flow Growth | 30.43% | 23.29% | 61.83% | -19.81% | 439.98% | - | Upgrade |
Capital Expenditures | -7.08 | -10.7 | -15.29 | -4.81 | -1.46 | -2.5 | Upgrade |
Sale of Property, Plant & Equipment | - | - | - | 26.01 | - | 1.08 | Upgrade |
Purchases of Investments | -597.82 | -647.6 | -292.91 | -255.21 | -652.52 | -226.19 | Upgrade |
Proceeds from Sale of Investments | 461.26 | 395.57 | 211.3 | 746.13 | 247.68 | 305.97 | Upgrade |
Payments for Business Acquisitions | - | - | - | -999.12 | - | - | Upgrade |
Investing Cash Flow | -143.64 | -262.72 | -96.91 | -487.01 | -406.29 | 78.35 | Upgrade |
Short-Term Debt Issued | - | - | - | 120 | - | - | Upgrade |
Short-Term Debt Repaid | - | - | - | -120 | - | - | Upgrade |
Long-Term Debt Issued | - | - | - | 250 | 784.88 | - | Upgrade |
Long-Term Debt Repaid | - | - | -13.48 | 374.55 | -369.06 | -19.56 | Upgrade |
Net Long-Term Debt Issued (Repaid) | - | - | -13.48 | 624.55 | 415.81 | -19.56 | Upgrade |
Issuance of Common Stock | - | 31.14 | 7.88 | 14.05 | 12.54 | 63.39 | Upgrade |
Repurchase of Common Stock | - | -250 | -402.38 | -200 | -350.06 | -150.12 | Upgrade |
Net Common Stock Issued (Repurchased) | - | -218.86 | -394.5 | -185.95 | -337.52 | -86.72 | Upgrade |
Other Financing Activities | - | - | - | -76.22 | -0.42 | - | Upgrade |
Financing Cash Flow | -530.14 | -218.86 | -407.99 | 362.37 | 77.87 | -106.28 | Upgrade |
Net Cash Flow | -126 | -2.52 | -116.33 | 115.48 | -28.98 | 27.52 | Upgrade |
Beginning Cash & Cash Equivalents | 187.86 | 118.37 | 234.7 | 119.22 | 148.2 | 120.68 | Upgrade |
Ending Cash & Cash Equivalents | 61.86 | 115.85 | 118.37 | 234.7 | 119.22 | 148.2 | Upgrade |
Free Cash Flow | 540.69 | 468.37 | 373.28 | 235.3 | 297.98 | 52.95 | Upgrade |
Free Cash Flow Growth | 15.44% | 25.47% | 58.64% | -21.04% | 462.76% | - | Upgrade |
FCF Margin | 45.87% | 46.13% | 45.01% | 35.65% | 67.22% | 19.79% | Upgrade |
Free Cash Flow Per Share | 4.24 | 3.62 | 2.78 | 1.67 | 2.03 | 0.37 | Upgrade |
Levered Free Cash Flow | 621.69 | 500.74 | 303.61 | 866.1 | 837.25 | 39.71 | Upgrade |
Unlevered Free Cash Flow | 614.08 | 496.23 | 308.4 | 256.67 | 465.82 | 74.19 | Upgrade |
Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.